Dementia is a global issue, with two-thirds of people with dementia living in low- and middle- income countries. Despite this, dementia research continues to focus on patients in high-income countries. Our guest on this episode, Dr. Riadh Gouider, is working to correct this imbalance. Dr. Gouider is the Head of the Department of Neurology and the Alzheimer Center at Razi Hospital in Tunisia and an advisor on the latest WHO Global Action Plan on the public health response to dementia. He spoke with Dr. Jayant Acharya, Professor and Chair of Neurology at Southern Illinois University School of Medicine -- about challenges, and opportunities, for dementia research across the globe. Series 6, Episode 3

Featuring:

• Guest: Dr. Riadh Gouider, Head of the Department of Neurology and the Alzheimer Center at Razi Hospital in Tunisia
• Interviewer: Dr. Jayant Acharya, Professor and Chair of Neurology at Southern Illinois University School of Medicine
• Disclosures: None

Below are the links to the publications discussed during this episode.

• Lancet Commission on Dementia: https://www.thelancet.com/commissions/dementia-prevention-intervention-care
• WHO Global Action Plan on Dementia: https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025

It used to be that surgery for medically refractory epilepsy was big, open and invasive, a treatment of last resort. The landscape has changed in recent decades, with more and more minimally invasive surgical approaches being developed. So what does this mean for the average patient with medically refractory epilepsy? Our guest today is Dr. Jon Willie, Associate Professor, Department of Neurological Surgery, Washington University School of Medicine in St. Louis. He speaks with Dr. Ionnis Karakis, Epileptologist and Adjunct Professor of Neurology at Emory University, about the new landscape of epilepsy surgery. Series 6, Episode 2

Featuring:

• Guest: Jon T. Willie, MD, PhD, FAANS, Associate Professor, Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri
• Interviewer: Ioannis Karakis, MD, PhD, MSc., Epileptologist and Adjunct Professor of Neurology at Emory University

Disclosures: Dr. Karakis disclosed that he is a consultant for USB, GSK, Ceribell, and Epitel. Dr. Willie disclosed Consulting for Clearpoint, Inc, AiM Medical Robotics, Inc., and Fortec Medical, Inc.; Contracted Research with Abbott, Inc., Neurona, Inc., and Neuropace, Inc.; and Honoraria from Medtronic, Inc.

Until recently, the Glymphatic System was a neglected corner of neuroscience. Now it’s increasingly clear that the brain’s system for the flow of fluid, nutrients, and waste plays an important role in sleep and brain disease. With glymphatics in the spotlight, researchers are coming up with innovative ways to study this slow, constant flow of cerebrospinal fluid throughout the brain. Dr. Daniel Claassen is a Professor of Neurology and Chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University, who researches the glymphatic system in humans. He’ll talk about new directions in glymphatics research with Dr. Cheran Elangovan, a Vascular Neurologist at the University of Tennessee Health Science Center. Series 6, Episode 1

Featuring:

• Guest: Dr. Daniel Claassen is a Professor of Neurology and Chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University
• Interviewer: Dr. Cheran Elangovan, a Vascular Neurologist at the University of Tennessee Health Science Center
• Disclosures: No relationships

Just last week, we wrapped up another exciting annual meeting of the American Neurological Association, ANA2024. Right before we packed up to head home, the President of the American Neurological Association, Dr. Betsy Ross, sat down with Dr. Allison Willis, the 2024 chair of the ANA’s Annual Meeting Programming Committee, to reflect on some of the highlights of this year's meeting. Series 5, Episode 12

Featuring:

• Guest: Dr. Allison Willis, the 2024 chair of the ANA’s Annual Meeting Programming Committee
• Interviewer: Dr. Betsy Ross, President of the American Neurological Association -
• Producer: Dr. Michelle Johansen, chair of the ANA's Education Innovation Committee
• Disclosures: None

Listen as Dr. Adeline Goss, Associate Chief of Neurology at Highland Hospital, discusses the groundbreaking potential of psychedelics in neurology with Dr. Steve Zeiler, a Vascular Neurologist and Associate Professor at Johns Hopkins, and Dr. Ghul Dölen, a Professor of Psychology and Neuroscience at UC Berkeley. The conversation explores the newfound excitement surrounding psychedelics like MDMA, LSD, and psilocybin for treating mood disorders like depression and neurologic conditions such as stroke recovery. The experts also delve into research showing psychedelics' ability to reopen critical periods in the brain, potentially revolutionizing therapeutic approaches for a range of neurologic and psychiatric conditions. Series 5, Episode 11

Featuring:

• Guests: Dr. Steve Zeiler, a Vascular Neurologist and Associate Professor at Johns Hopkins, and Dr. Ghul Dölen, a Professor of Psychology and Neuroscience at UC Berkeley
• Interviewer: Dr. Adeline Goss, host & executive producer of ANA Investigates and Associate Chief of Neurology at Highland Hospital
• Disclosures: Dr. Dolen & Zeiler share a patent on their work in psychdelics and rehab. Dr. Zeiler also reports research funding from Harmon and EVER Pharma.

AI is everywhere, whether you are a fan of it or not. This month, join us for a deep dive into the AI revolution with our guest Dr. Ethan Mollick, professor at The Wharton School at the University of Pennsylvania and author of the New York Times bestseller, "Co-Intelligence." Discover how this AI revolution stands apart from past technological advancements and how it is transforming academic research. Ethan was interviewed for this episode by Dr. Zach London, an Associate Professor at the University of Michigan Medical School.

There has been tremendous progress in recent decades in the management of ischemic strokes. Meanwhile, hemorrhagic strokes have stubbornly resisted this progress. Interventions for these types of strokes have failed again and again to show a benefit over standard medical management, until this year. The recently published ENRICH trial is the first to show that minimally invasive neurosurgery may improve functional outcomes for patients with hemorrhagic stroke. Study lead author, Dr. Gustavo Pradilla joins us today to talk about the differences between ENRICH and previous negative trials, and future neurosurgical approaches for spontaneous intracerebral hemorrhage. Dr. Pradilla is a Professor of Neurosurgery, Otolaryngology, and Head and Neck Surgery at Emory University School of Medicine and Chief of Neurosurgery at Grady Memorial Hospital. He spoke to Dr. Masoom J. Desai, neurointensivist and Assistant Professor of Neurology at the University of New Mexico. Series 5, Episode 9

Featuring:

• Guest: Dr. Gustavo Pradilla, Emory University School of Medicine & Grady Memorial Hospital
• Interviewer: Dr. Masoom Desai, University of New Mexico

2024 has been a year of exciting trials on minimally invasive techniques in intracranial hemorrhage. This month we're focusing on Chronic Subdural Hematoma, where a minimally invasive strategy called Middle Meningeal Artery (MMA) Embolization is offering expanded treatment options for select patients. Dr. Chris Kellner is a cerebrovascular neurosurgeon and associate professor of neurosurgery at Mount Sinai. He'll talk about the promise of MMA embolization with Dr. Sarah Nelson, neurointensivist and neurohospitalist at Tufts Medical Center. We'll have more on these trials on the podcast in our June episode as well, with a focus next month on Minimally Invasive Techniques in Spontaneous Intracerebral Hemorrhage. Series 5, Episode 8

Featuring:

• Guest: Dr. Chris Kellner, a cerebrovascular neurosurgeon from Mount Sinai
• Interviewer: Dr. Sarah Nelson, a neurointensivist and neurohospitalist at Tufts Medical Center
• Disclosures: Dr. Kellner is the PI for two studies discussed during the podcast funding was received from Medtronic and Cerenovus.